Clinical Trial Detail

NCT ID NCT01911325
Title Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Buparlisib

Docetaxel

Age Groups: adult

No variant requirements are available.